Pay in 4 interest-free payments of $7.43 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
IGF-1 LR3 is more potent than regular IGF-1 because of the decreased binding of Long R3 IGF-1 to IGF binding proteins, allowing it to remain active up to 120 times longer compared to native IGF-1
These impurities aren't just inert filler
Studies have shown that it remains effective and works systemically this way (1, 19)
A 2025 pilot study tested IV BPC-157 up to 20 mg in 2 healthy adults for safety only, finding it well tolerated but conducting no efficacy testing
human clinical trials ongoing as of 2026 Search volume: 165,000 monthly US searches most searched non-weight-loss peptide Legal status: Category 1 compounding (legal under physician prescription, as of February 2026) Administration: Subcutaneous injection or oral/sublingual (gut applications) An honest note on the evidence: The majority of BPC-157 research has been conducted in animal models rats and mice primarily
